论文部分内容阅读
目的分析研究C-erbB-2、p53、ER、PR在乳腺癌中的表达与分期、转移关系及临床意义。方法用免疫组化法测定83例原发性乳腺癌C-erbB-2、p53、ER、PR的表达情况,进行对照比较。结果C-erbB-2、p53、ER、PR阳性表达者分别为30例(36.1%)、31例(37.3%)、45例(54.2%)、53例(63.9%)。C-erbB-2的表达与p53呈正相关(P<0.05),与ER、PR呈负相关(P<0.05)。C-erbB-2和p53的表达率随着临床分期增加和淋巴结转移而增加,差异有显著性(P<0.05)。ER、PR阳性表达率随着临床分期的递增和淋巴结转移的减少而降低,差异无显著性(P>0.05)。ER、PR阳性表达率与C-erbB-2、p53表达呈负相关,差异无显著性(P>0.05)。结论C-erbB-2、p53是判断乳腺癌预后的有效指标,ER、PR与临床分期及腋窝淋巴结转移有一定关系,联合检测C-erbB-2、p53、ER、PR可指导临床综合治疗。
Objective To study the expression, staging, metastasis and clinical significance of C-erbB-2, p53, ER and PR in breast cancer. Methods The expression of C-erbB-2, p53, ER and PR in 83 cases of primary breast cancer was detected by immunohistochemistry. Results The positive expression rates of C-erbB-2, p53, ER and PR were 30 (36.1%), 31 (37.3%), 45 (54.2%) and 53 (63.9%) respectively. The expression of C-erbB-2 was positively correlated with p53 (P <0.05), negatively correlated with ER and PR (P <0.05). The expression of C-erbB-2 and p53 increased with the increase of clinical stage and lymph node metastasis, the difference was significant (P <0.05). The positive rate of ER and PR decreased with the increase of clinical stage and the decrease of lymph node metastasis, with no significant difference (P> 0.05). The positive rates of ER and PR were negatively correlated with the expressions of C-erbB-2 and p53 (P> 0.05). Conclusions C-erbB-2 and p53 are effective indicators for predicting the prognosis of breast cancer. ER and PR have some relationship with clinical stage and axillary lymph node metastasis. Combined detection of C-erbB-2, p53, ER and PR may guide the clinical treatment.